CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Oxaliplatin

奥沙利铂 杂质对照品Oxaliplatin Impurities

EP27 个杂质条目27 impurity entries

本页汇总 奥沙利铂 的 27 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 27 impurity reference standards of Oxaliplatin with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 奥沙利铂(Oxaliplatin)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesClass IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer
    Molecular oncology · 2026 · Tolotto V et al.  ·  PMID 41174352  ·  DOI
  2. 杂质研究Impurity studiesRBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability
    Oncogene · 2026 · Ma Y et al.  ·  PMID 41354714  ·  DOI
  3. 杂质研究Impurity studiesNDRG2 orchestrates circadian clock stability to suppress tumorigenesis and potentiate oxaliplatin response in colorectal cancer
    Oncogene · 2026 · Li R et al.  ·  PMID 42156989  ·  DOI
  4. 分析方法Analytical MethodsDetermination of Oxaliplatin and Curcumin in Combination via Micellar HPLC and Its Method Validation
    Journal of AOAC International · 2022 · Tiwari A et al.  ·  PMID 35353135  ·  DOI
  5. 分析方法Analytical MethodsArtificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin
    JCO precision oncology · 2025 · Kim H et al.  ·  PMID 41037761  ·  DOI

奥沙利铂 —— 原料药与杂质对照品Oxaliplatin — drug substance & impurities

共 28 个条目(含原料药本体)28 items incl. the drug substance
Oxaliplatin structure
EP原料药 APIAPI
奥沙利铂Oxaliplatin
Oxaliplatin
CAS No.61825-94-3
Chemical FormulaC8H14N2O4Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 1 Diammonium (Oxaliplatin EP Impurity A Diammonium) structure
EPA
奥沙利铂杂质1 二铵盐 (奥沙利铂EP杂质A 二铵盐)Oxaliplatin Impurity 1 Diammonium (Oxaliplatin EP Impurity A Diammonium)
Oxaliplatin Impurity 1 Diammonium (Oxaliplatin EP Impurity A Diammonium)
CAS No.6009-70-7
Chemical FormulaC2H2O4·2(NH3)·H2O
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 1 Dihydrate (Oxaliplatin EP Impurity A Dihydrate) structure
EPA
奥沙利铂杂质1 二水合物 (奥沙利铂EP杂质A 二水合物)Oxaliplatin Impurity 1 Dihydrate (Oxaliplatin EP Impurity A Dihydrate)
Oxaliplatin Impurity 1 Dihydrate (Oxaliplatin EP Impurity A Dihydrate)
CAS No.6153-56-6
Chemical FormulaC2H2O4·2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 2(Oxaliplatin EP Impurity B) structure
EPB
奥沙利铂杂质2(奥沙利铂EP杂质B)Oxaliplatin Impurity 2(Oxaliplatin EP Impurity B)
Oxaliplatin Impurity 2(Oxaliplatin EP Impurity B)
CAS No.89955-85-1
Chemical FormulaC6H18N2O2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 2 Dinitrate(Oxaliplatin EP Impurity B Dinitrate) structure
EPB
奥沙利铂杂质2二硝酸盐(奥沙利铂EP杂质B二硝酸盐)Oxaliplatin Impurity 2 Dinitrate(Oxaliplatin EP Impurity B Dinitrate)
Oxaliplatin Impurity 2 Dinitrate(Oxaliplatin EP Impurity B Dinitrate)
CAS No.94042-08-7
Chemical FormulaC6H18N4O8Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 3(Oxaliplatin EP Impurity C) structure
EPC
奥沙利铂杂质3(奥沙利铂EP杂质C)Oxaliplatin Impurity 3(Oxaliplatin EP Impurity C)
Oxaliplatin Impurity 3(Oxaliplatin EP Impurity C)
CAS No.111321-67-6
Chemical FormulaC8H16N2O6Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 4 (Oxaliplatin EP Impurity D) structure
EPD
奥沙利铂杂质4 (奥沙利铂EP杂质D)Oxaliplatin Impurity 4 (Oxaliplatin EP Impurity D)
Oxaliplatin Impurity 4 (Oxaliplatin EP Impurity D)
CAS No.61758-77-8
Chemical FormulaC8H14N2O4Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 5 Dinitrate(Oxaliplatin EP Impurity E Dinitrate) structure
EPE
奥沙利铂杂质5二硝酸盐(奥沙利铂EP杂质E二硝酸盐)Oxaliplatin Impurity 5 Dinitrate(Oxaliplatin EP Impurity E Dinitrate)
Oxaliplatin Impurity 5 Dinitrate(Oxaliplatin EP Impurity E Dinitrate)
CAS No.82398-34-3
Chemical FormulaC12H30N6O8Pt2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 1-13C2 Dihydrate (Oxaliplatin EP Impurity A-13C2 Dihydrate) structure
EPA-13C2
奥沙利铂杂质1-13C2 二水合物 (奥沙利铂EP杂质A-13C2 二水合物)Oxaliplatin Impurity 1-13C2 Dihydrate (Oxaliplatin EP Impurity A-13C2 Dihydrate)
Oxaliplatin Impurity 1-13C2 Dihydrate (Oxaliplatin EP Impurity A-13C2 Dihydrate)
CAS No.286367-59-7
Chemical Formula13C2H2O4·2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Miriplatin Impurity 3 structure
3
米铂杂质3Miriplatin Impurity 3
Miriplatin Impurity 3
CAS No.61848-62-2
Chemical FormulaC6H14Cl2N2Pt
Purity>95%现货In stock
10mg25mg50mg100mg
Oxaliplatin Impurity 8 structure
8
奥沙利铂杂质8Oxaliplatin Impurity 8
Oxaliplatin Impurity 8
CAS No.62535-06-2
Chemical FormulaC8H32Cl6N8O16Pt2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 9 structure
9
奥沙利铂杂质9Oxaliplatin Impurity 9
Oxaliplatin Impurity 9
CAS No.61848-66-6
Chemical FormulaC6H14Cl2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 10 structure
10
奥沙利铂杂质10Oxaliplatin Impurity 10
Oxaliplatin Impurity 10
CAS No.66900-68-3
Chemical FormulaC6H14N4O6Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 11 structure
11
奥沙利铂杂质11Oxaliplatin Impurity 11
Oxaliplatin Impurity 11
CAS No.121958-12-1
Chemical FormulaC6H14I2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 12 structure
12
奥沙利铂杂质12Oxaliplatin Impurity 12
Oxaliplatin Impurity 12
CAS No.1017265-31-4
Chemical FormulaC8H16N2O5Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 13  Monomer structure
13
奥沙利铂杂质13 单体Oxaliplatin Impurity 13 Monomer
Oxaliplatin Impurity 13 Monomer
CAS No.117604-38-3
Chemical FormulaC6H16ClN2OPt+
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 13 structure
13
奥沙利铂杂质13Oxaliplatin Impurity 13
Oxaliplatin Impurity 13
CAS No.1421704-68-8
Chemical FormulaC6H16ClN2OPt+·NO3-
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 14 structure
14
奥沙利铂杂质14Oxaliplatin Impurity 14
Oxaliplatin Impurity 14
CAS No.52691-24-4
Chemical FormulaC6H14Cl2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 15 structure
15
奥沙利铂杂质15Oxaliplatin Impurity 15
Oxaliplatin Impurity 15
CAS No.1121-22-8
Chemical FormulaC6H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 16 structure
16
奥沙利铂杂质16Oxaliplatin Impurity 16
Oxaliplatin Impurity 16
CAS No.20439-47-8
Chemical FormulaC6H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 17 structure
17
奥沙利铂杂质17Oxaliplatin Impurity 17
Oxaliplatin Impurity 17
CAS No.1436-59-5
Chemical FormulaC6H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 18 structure
18
奥沙利铂杂质18Oxaliplatin Impurity 18
Oxaliplatin Impurity 18
CAS No.21436-03-3
Chemical FormulaC6H14N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 19 structure
19
奥沙利铂杂质19Oxaliplatin Impurity 19
Oxaliplatin Impurity 19
CAS No.66845-32-7
Chemical FormulaC6H14I2N2Pt
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 20 structure
20
奥沙利铂杂质20Oxaliplatin Impurity 20
Oxaliplatin Impurity 20
CAS No.53152-69-5
Chemical FormulaC10H22N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 21 structure
21
奥沙利铂杂质21Oxaliplatin Impurity 21
Oxaliplatin Impurity 21
CAS No.68737-65-5
Chemical FormulaC8H18N2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 24 structure
24
奥沙利铂杂质24Oxaliplatin Impurity 24
Oxaliplatin Impurity 24
CAS No.1613307-37-1
Chemical FormulaC20H28N2O6PtS2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 25 structure
25
奥沙利铂杂质25Oxaliplatin Impurity 25
Oxaliplatin Impurity 25
CAS No.65296-78-8
Chemical FormulaC20H28N2O6PtS2
Purity>95%询价On request
10mg25mg50mg100mg
Oxaliplatin Impurity 28 structure
28
奥沙利铂杂质28Oxaliplatin Impurity 28
Oxaliplatin Impurity 28
CAS No.67579-81-1
Chemical FormulaC8H18N2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

奥沙利铂 —— 研究文献与合成路线Oxaliplatin — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 奥沙利铂 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Oxaliplatin. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Class IIa HDACs forced degradation allows resensitization of oxaliplatin-resistant FBXW7-mutated colorectal cancer
    Tolotto V, Gualandi N, Cortolezzis Y, et al. · Molecular oncology · 2026 · 被引 1cited 1
  2. The E3 ligase HUWE1 increases the sensitivity of CRC to oxaliplatin through TOMM20 degradation
    Lee C, Park SH, Yoon SK · Oncogene · 2024 · 被引 10cited 10
  3. The degradation pathways in chloride medium of the third generation anticancer drug oxaliplatin
    Alberto ME, Lucas MF, Pavelka M, et al. · The journal of physical chemistry. B · 2008 · 被引 15cited 15
  4. GL-V9 synergizes with oxaliplatin of colorectal cancer via Wee1 degradation mediated by HSP90 inhibition
    Chen H, Yang F, Zhao Q, et al. · The Journal of pharmacy and pharmacology · 2024 · 被引 5cited 5
  5. EXAFS characterization of oxaliplatin anticancer drug and its degradation in chloride media
    Bouvet D, Michalowicz A, Crauste-Manciet S, et al. · Journal of synchrotron radiation · 2006 · 被引 10cited 10
  6. Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation
    Zhang R, Luo W, Zhou Q, et al. · Experimental hematology & oncology · 2026

合成与制备工艺专利Synthesis & process patents

  1. Method for preparing oxaliplatin
    JURONG YU, JIE YANG, BIN XU, QING LI · 公开号 CN101633673CN101633673 · 2010
  2. OXALIPLATIN NANOPARTICLES AND METHOD FOR PREPARING SAME
    LEE SUNG JAE, KIM YOUNG HOON, LEE SANG HEON, KIM KAB SIG · 公开号 WO2011034394WO2011034394 · 2011
  3. A process for the preparation of an oxaliplatin
    KACER PETR, MENGLER JAN, CERVENY LIBOR, KYSILKA VLADIMIR · 公开号 AU2006344273AU2006344273 · 2007
  4. A PROCESS FOR THE PREPARATION OF AN OXALIPLATIN
    MENGLER JAN, KYSILKA VLADIMIR, CERVENY LIBOR, KACER PETR · 公开号 CA2652641CA2652641 · 2007
  5. PROCESS FOR THE PREPARATION OF AN OXALIPLATIN
    KYSILKA VLADIMIR, MENGLER JAN, KACER PETR, CERVENY LIBOR · 公开号 US2010174102US2010174102 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

奥沙利铂 杂质谱研究要点Oxaliplatin — impurity profiling notes

下面这些是拿到 奥沙利铂 的 28 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 28 impurity entries for Oxaliplatin, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances